Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

European Journal of Clinical Pharmacology

Volumn 53, Issue 6, 1998, Pages 469-473

  Muck W ^a   Ochmann, K ^a   Rohde, G ^a   Unger, S ^a   Kuhlmann, J ^a  

^a BAYER AG   (Germany)

Author keywords

Cerivastatin; Cytochrome P450 3A4 inhibition

Indexed keywords

CERIVASTATIN; ERYTHROMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROTEIN SYNTHESIS INHIBITORS; PYRIDINES; REFERENCE VALUES;

EID: 0031969657     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050408     Document Type: Article

References (24)

1. Pedersen TR, Kjekshus J, Berg K, et al (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
2. Shepherd J, Cobbe SM, Ford I, et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med 333: 1301-1307
3. Angerbauer R, Bischoff H, Steinke W, Ritter W (1994) BAY w 6228. Drugs Future 19: 537-541
4. Stein E, Sprecher D, Allenby KS, Tosiello RL (1997) Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 2: 7-16
5. Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35: 255-260
6. 14C]BAY w 6228: biotransformation in human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331
7. Bischoff H, Angerbauer R, Boberg M, Schmidt D (1997) Cerivastatin: high enzyme affinity and active metabolites contribute to its high pharmacological activity (abstract no. 93). Atherosclerosis 130 [Suppl]: S25
8. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35: 261-264
9. von Rosenstiel NA, Adam D (1995) Macrolide antibacterials drug interactions of clinical significance. Drug Safety 13: 105-122
10. Spach DH, Bauwens JE, Clark CD, Burke WG (1991) Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 154: 213-215
11. Lees RS, Lees AM (1995) Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 333: 664-665
12. Neuvonen PJ, Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60: 54-61
13. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP (1991) Biotransformation of lovastatin: identification of cytochrome P-450 3A protein as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290: 355-361
14. Krol GJ, Beck GW, Ritter W, Lettieri JT (1993) LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
15. Birkett DJ, Robson RA, Grgurinovich N, Tonkin A (1990) Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther Drug Monit 12: 65-71
16. Transon C, Leeman T, Dayer P (1996) In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50: 209-215
17. Yang BB, Siedlik PH, Smithers JA, Sedman AJ, Stern RH (1996) Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol. Pharm Res 13 [suppl]: S437
18. Bottorf MB, Behrens DH, Gross A, Markel MB (1997) Differences in metabolism of lovastatin and pravastatin as assessed by CYP3A inhibition by erythromycin. Pharmacotherapy 17: 184
19. Segaert MF, De Soete C, Vandewiele I, Verbanck J (1996) Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 11: 1846-1847
20. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A, Vigano M (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25: 2732-2734
21. Arnadottir M, Eriksson LO, Thysell H, Karkas JD (1993) Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 65: 410-413
22. Kobashigawa JA, Murphy FL, Stevenson LW (1990) Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 82: 281-283
23. Tobert JA (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 318: 48
24. Tucker GT (1992) The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther 30: 550-553